The effect of anti-AFP-F(ab)'2 and adriamycin conjugate on transplantable tumors in mice.
Efficacy of the conjugate anti-AFP-F(ab)'2 with adriamycin, anti-AFP-F(ab)'2-adr, against transplantable tumors was studied in mice. The results showed that LD50 of anti-AFP-F(ab)'2-adr in mice was 7.43 mg/kg and that anti-AFP-F(ab)'2-adr in a dose of 1/10-1/5 LD50 could inhibit the growth of transplanted hepatocellular carcinoma. In addition, anti-AFP-F(ab)'2-adr with local application of AFP could markedly inhibit the growth of transplanted Ehrlich ascites cancer. From the above it is suggested that anti-AFP-F(ab)'2-adr can be used to treat hepatic carcinoma with satisfactory results.